Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Longeveron (NASDAQ: LGVN) will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after U.S. market close.
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference call number: 1.877.407.0789 with Conference ID 13759888. A replay will be available in the Events & Presentations section of the company website following the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LGVN
On May 6, the first trading day after this news, LGVN closed 2.09% above the previous close.
Data tracked by StockTitan Argus for the May 6 session.
Key Figures
- Earnings date
- May 13, 2026
- 2026 first quarter financial results release after U.S. market close
- Conference time
- 4:30 p.m. ET
- Start time for Q1 2026 results conference call and webcast
- Conference call number
- 1.877.407.0789
- Dial-in number for the Q1 2026 earnings conference call
- Conference ID
- 13759888
- Access code for joining the Q1 2026 earnings call
Previous Conferences,earnings date Reports
-
Announcement of date and time for 2025 full-year results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference Call and Webcast Details:
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13759888 |
| Call me™ Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.